Form 4: Abbott Laboratories Director Patricia Paola Gonzalez Reports Acquisition of Stock Equivalent Units

Director Patricia Paola Gonzalez reports acquisition of 289 stock equivalent units in Abbott Laboratories through director fees credited to a grantor trust.

Summary

• On September 30, 2024, Patricia Paola Gonzalez, a director of Abbott Laboratories, acquired 289 stock equivalent units.
• These units were obtained as director fees credited to a stock equivalent unit account under a grantor trust.
• The price of the transaction was $114.01 per unit.
• Following the transaction, Gonzalez directly owns 3,815 stock equivalent units, including those acquired through dividend reinvestment.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects a director's continued investment in the company, indicating confidence. It's a routine transaction, so the impact is moderate.

Positives

• The acquisition of stock equivalent units demonstrates the director's continued investment in Abbott Laboratories.
• The dividend reinvestment feature further increases the director's stake in the company.

Industry Context

This filing is a routine disclosure of a director's acquisition of stock equivalent units, which is a common practice for compensating board members.

Stakeholder Impact

• The transaction signals to shareholders that a director is aligned with the company's long-term interests.

Key Dates